The Conference Board analysts say the question isn’t why China will slow, but why anyone thinks it won’t
Tablets remain a problem in a record-breaking quarter
From Michael Dunn's trial in Florida to discord over open-carry laws in Colorado, the debate about gun control has driven Americans to indulge their worst behavior
The company misses earnings forecasts, drops its 2015 profit goal, and regroups
Chinese millionaires are moving in—and building up—in Arcadia, Calif.
A new book surveys the best places to hide out from the digital world
The two tech giants fight over market share and patents but not over the NBA superstar
Harvard Law School graduates make more money than alumni of any other graduate or professional school. That doesn't mean all lawyers fare well
Small businesses are changing hands at the fastest pace since the recession
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."